

|
¡Ø ÈÇиí : Benztropine mesylate, 98%
¡Ø µî±Þ : APIs and Bioactives > AChR Agonists
¡Ø ÆÇ¸Å Æ÷Àå´ÜÀ§ : 1g , 5g
¡Ø ÈÇÐ½Ä : C21H25NO.CH4O3S
¡Ø CAS # : [132-17-2]
|
| IDENTITY |
|
| CAS Registry #: |
[132-17-2] |
| MDL Number: |
MFCD00074784 |
| MF: |
C21H25NO.CH4O3S |
| MW: |
403.535 |
| EINECS: |
205-048-8 | |
| SPECIFICATIONS & PROPERTIES |
|
| Purity: |
98% |
| Physical Form: |
White to off-white powder |
| Melting Point: |
133-135¡ÆC |
| Long-Term Storage: |
Store long-term at 2-8¡ÆC |
| Shipping: |
Regulated for Shipping |
| UN #: |
2811 |
| Hazard Class: |
6.1 |
| Packing Group: |
III | | |
BIOLOGICAL INFO |
|
| Application(s): |
Dopamine transporter (DAT) inhibitor |
REVIEWBenztropine is a selective M1 muscarinic acetylcholine receptor antagonist. It is able to discriminate between the M1 (cortical or neuronal) and the peripheral muscarinic subtypes (cardiac and glandular). Benztropine partially blocks cholinergic activity in the CNS, which is responsible for the symptoms of Parkinsons disease. It is also thought to increase the availability of dopamine, a brain chemical that is critical in the initiation and smooth control of voluntary muscle movement.
REFERENCES
[1] |
Wszola BA, Newell KM, Sprague RL: Risk factors for tardive dyskinesia in a large population of youths and adults. Exp Clin Psychopharmacol. 2001 Aug;9(3):285-96. |
| [2] |
van Harten PN, Hoek HW, Matroos GE, Koeter M, Kahn RS: Intermittent neuroleptic treatment and risk for tardive dyskinesia: Curacao Extrapyramidal Syndromes Study III. Am J Psychiatry. 1998 Apr;155(4):565-7. |
Risk Description(s)
| R23/24/25: |
Toxic by inhalation, in contact with skin and if swallowed |
Safety Description(s)
| S36/37/39: |
Wear suitable protective clothing, gloves and eye/face protection. |
| S45: |
In case of accident or if you feel unwell, seek medical advice immediately (show the label where possible). |


°í¾×°áÁ¦ÀÇ °æ¿ì ¾ÈÀüÀ» À§ÇØ Ä«µå»ç¿¡¼ È®ÀÎÀüȸ¦ µå¸± ¼öµµ ÀÖ½À´Ï´Ù. È®ÀΰúÁ¤¿¡¼ µµ³ Ä«µåÀÇ »ç¿ëÀ̳ª ŸÀÎ ¸íÀÇÀÇ ÁÖ¹®µî Á¤»óÀûÀÎ ÁÖ¹®ÀÌ ¾Æ´Ï¶ó°í ÆÇ´ÜµÉ °æ¿ì ÀÓÀÇ·Î ÁÖ¹®À» º¸·ù ¶Ç´Â Ãë¼ÒÇÒ ¼ö ÀÖ½À´Ï´Ù.
¹«ÅëÀå ÀÔ±ÝÀº »óǰ ±¸¸Å ´ë±ÝÀº PC¹ðÅ·, ÀÎÅͳݹðÅ·, ÅÚ·¹¹ðÅ· ȤÀº °¡±î¿î ÀºÇà¿¡¼ Á÷Á¢ ÀÔ±ÝÇÏ½Ã¸é µË´Ï´Ù.
ÁÖ¹®½Ã ÀÔ·ÂÇÑ ÀÔ±ÝÀÚ¸í°ú ½ÇÁ¦ÀÔ±ÝÀÚÀÇ ¼º¸íÀÌ ¹Ýµå½Ã ÀÏÄ¡ÇÏ¿©¾ß Çϸç, 7ÀÏ À̳»·Î ÀÔ±ÝÀ» ÇÏ¼Å¾ß Çϸç ÀԱݵÇÁö ¾ÊÀº ÁÖ¹®Àº ÀÚµ¿Ãë¼Ò µË´Ï´Ù.
¹è¼Û ¹æ¹ý : ÅÃ¹è ¹× Á÷³³
¹è¼Û Áö¿ª : Àü±¹
¹è¼Û ºñ¿ë : ÃÑ ±¸¸Å ºñ¿ëÀÌ £Ü100,000 (VATº°µµ) ¹Ì¸¸ÀÏ °æ¿ì ÂøºÒ·Î ¹ß¼Û
¹è¼Û ±â°£ : ±¹»êǰ (3~7ÀÏ), ¼öÀÔǰ (7~14ÀÏ)
¹è¼Û ¾È³»
- »ê°£º®Áö³ª µµ¼Áö¹æÀº º°µµÀÇ Ãß°¡±Ý¾×À» ÁöºÒÇÏ¼Å¾ß ÇÏ´Â °æ¿ì°¡ ÀÖ½À´Ï´Ù.
°í°´´Ô²²¼ ÁÖ¹®ÇϽŠ»óǰÀº ÀÔ±Ý È®ÀÎÈÄ ¹è¼ÛÇØ µå¸³´Ï´Ù. ´Ù¸¸, »óǰÁ¾·ù¿¡ µû¶ó¼ »óǰÀÇ ¹è¼ÛÀÌ ´Ù¼Ò Áö¿¬µÉ ¼ö ÀÖ½À´Ï´Ù.


±³È¯ ¹× ¹ÝǰÀÌ °¡´ÉÇÑ °æ¿ì
- »óǰÀ» °ø±Þ ¹ÞÀ¸½Å ³¯·ÎºÎÅÍ 7ÀÏÀ̳»
±³È¯ ¹× ¹ÝǰÀÌ ºÒ°¡´ÉÇÑ °æ¿ì
- °í°´´ÔÀÇ Ã¥ÀÓ ÀÖ´Â »çÀ¯·Î »óǰµîÀÌ ¸ê½Ç ¶Ç´Â ÈÑ¼ÕµÈ °æ¿ì
- Æ÷ÀåÀ» °³ºÀÇÏ¿´°Å³ª Æ÷ÀåÀÌ ÈÑ¼ÕµÇ¾î »óǰ°¡Ä¡°¡ »ó½ÇµÈ °æ¿ì
- ½Ã°£ÀÇ °æ°ú¿¡ ÀÇÇÏ¿© ÀçÆÇ¸Å°¡ °ï¶õÇÒ Á¤µµ·Î »óǰµîÀÇ °¡Ä¡°¡ ÇöÀúÈ÷ °¨¼ÒÇÑ °æ¿ì
- ¿Âµµ°ü¸®Ç° ¹× ¼öÀÔǰÀº ¹ÝǰÀÌ ºÒ°¡´ÉÇÕ´Ï´Ù.
¡Ø ÁÖ¹® Ãë¼Ò ¹× ¹ÝǰÀ¸·Î ȯºÒÀ» ¿äûÇÏ½Ç °æ¿ì¿¡´Â E-mail(info@syinnovation.co.kr) »ó´ã¼ºñ½º³ª °í°´¸¸Á·¼¾ÅÍ(070-4829-4101)¸¦ ÅëÇØ ¿äûÇϽøé Ä£ÀýÇÏ°Ô Ã³¸®ÇØ µå¸®°Ú½À´Ï´Ù.